Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation

Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation

BackgroundAumolertinib is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with proven efficacy and safety for untreated non-small-cell lung cancer (NSCLC) patients with EGFR sensitizing mutations (EGFRm) in China. The progression-free survival (PFS) imp...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lingping Kong, Lina Peng, Xue Yang, Qing Ma, Linlin Zhang, Xia Liu, Diansheng Zhong, Fanlu Meng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Oncology
Subjects:	aumolertinib bevacizumab EGFR-TKI non-small cell lung cancer progression-free survival
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1595812/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
by: Shun Lu, et al.
Published: (2024-09-01)

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
by: Yingqi Xu, et al.
Published: (2025-12-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01)

The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia
by: Elisna Syahruddin, et al.
Published: (2025-01-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment
by: Rui FAN, et al.
Published: (2025-05-01)

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01)

Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
by: Laura S. Puuniemi, et al.
Published: (2025-07-01)

Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations
by: Atsuto Mouri, et al.
Published: (2025-07-01)

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
by: Y. Uehara, et al.
Published: (2024-09-01)

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01)

Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI
by: Yiming ZENG, et al.
Published: (2025-06-01)

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset
by: Makoto Nishio, MD, PhD, et al.
Published: (2025-06-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
by: Olivier Calvayrac, et al.
Published: (2016-12-01)

New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era
by: Jaime Rubio-Perez, et al.
Published: (2025-01-01)

Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature
by: Blerina Resuli, et al.
Published: (2025-05-01)

Survival Outcomes in EGFR‐Mutant Non‐Small Cell Lung Cancer With Brain Metastases: Kaplan–Meier and Cox Regression Analyses Across Treatment Stages
by: Haoran Qi, et al.
Published: (2025-05-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)

Recent Advances in the Use of <i>Ganoderma lucidum</i> and <i>Coriolus versicolor</i> Mushrooms to Enhance the Anticancer Efficacy of EGFR-Targeted Drugs in Lung Cancer
by: Hang Zhang, et al.
Published: (2025-07-01)

A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer
by: Jianqiong Yin, et al.
Published: (2025-03-01)

Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer
by: Yuhong Ma, et al.
Published: (2024-12-01)

Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer
by: Chen CY, et al.
Published: (2025-04-01)

Identification of expression profiles and transcription factors during EGFR‐TKI acquired resistance in LUAD
by: Lili Feng, et al.
Published: (2024-12-01)

Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling
by: Jiahui Wu, et al.
Published: (2022-04-01)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
by: Bożena Cybulska-Stopa, et al.
Published: (2020-03-01)

Advanced lung adenocarcinoma harboring uncommon EGFR 19 Del and T790M/trans-C797S mutations after resistance: a case report and literature review
by: Yuting Xiao, et al.
Published: (2025-04-01)

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
by: Huiling Su, et al.
Published: (2025-02-01)

Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial
by: Huiyang Shi, et al.
Published: (2025-08-01)

EMP3 is upregulated upon epithelial–mesenchymal transition and contributes to EGFR–tyrosine kinase inhibitor resistance in lung adenocarcinoma
by: Chunyan Wang, et al.
Published: (2025-07-01)

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
by: Han X, et al.
Published: (2024-11-01)

CircSPINT2 confers sensitivity to osimertinib via hsa-miR-1296-3p/RBP1 axis and inhibits NSCLC progression
by: Nalini Devi Verusingam, et al.
Published: (2025-09-01)

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
by: Jixian Li, et al.
Published: (2025-07-01)

TRANS: a prediction model for EGFR mutation status in NSCLC based on radiomics and clinical features
by: Zhigang Chen, et al.
Published: (2025-06-01)

HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells
by: Hanbing Lyu, et al.
Published: (2025-06-01)